[Comment] Clemastine fumarate for promotion of optic nerve remyelination

The regulatory approval of 15 disease-modifying medications to reduce inflammatory lesion activity in relapsing multiple sclerosis illustrates the dramatic progress made in the treatment of this frequently disabling condition. None of these medications, however, directly promotes repair of the damaged CNS. As a result, therapies to prevent accumulation of permanent disability and, especially, to reverse pre-existing disability represent major unmet needs.
Source: LANCET - Category: General Medicine Authors: Tags: Comment Source Type: research